Abstract
Comorbid chronic rhinosinusitis and/or nasal polyposis (CRS/NP) substantially adds to the disease burden in patients with asthma. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. Dupilumab is approved for asthma and CRS with NP. The TRAVERSE (NCT02134028) open-label extension study evaluated long-term safety and tolerability of add-on dupilumab in adult/adolescent patients with asthma who participated in a previous dupilumab asthma study.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
